Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
12.06.2007
Scandals at IQWIG?
It hasn't been an easy autumn for the German IQWIG institute. The local press is full of talk around the recent rumors of IQWIG's head favoring a family company with research projects from his institute- and other issues related to the institute's leaders management and communication style have layered darck clouds over IQWIG. http://www.dfg-online.de/ and others are reporting on the matter...
No comments:
Post a Comment